ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone310-388-6706
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.56 million
Profitability
Miscellaneous
Employees100
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Chromadex (NASDAQ:CDXC) Frequently Asked Questions
What is Chromadex's stock symbol?
Chromadex trades on the NASDAQ under the ticker symbol "CDXC."
How were Chromadex's earnings last quarter?
Chromadex Corp (NASDAQ:CDXC) released its earnings results on Thursday, March, 7th. The company reported ($0.15) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.01. The firm earned $9.07 million during the quarter, compared to the consensus estimate of $9.21 million. Chromadex had a negative net margin of 105.57% and a negative return on equity of 90.20%. View Chromadex's Earnings History.
When is Chromadex's next earnings date?
What price target have analysts set for CDXC?
2 brokers have issued twelve-month price targets for Chromadex's shares. Their predictions range from $7.00 to $7.00. On average, they anticipate Chromadex's share price to reach $7.00 in the next year. This suggests a possible upside of 75.2% from the stock's current price. View Analyst Price Targets for Chromadex.
What is the consensus analysts' recommendation for Chromadex?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chromadex.
Has Chromadex been receiving favorable news coverage?
News headlines about CDXC stock have trended negative on Monday, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chromadex earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the near future.
Who are some of Chromadex's key competitors?
Some companies that are related to Chromadex include CV Sciences (CVSI), Canopy Rivers (RIV), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), Cyanotech (CYAN), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), FitLife Brands (FTLF), True Drinks (TRUU), Nutra Pharma (NPHC), Entia Biosciences (ERGO) and Beleave (BE).
What other stocks do shareholders of Chromadex own?
Who are Chromadex's key executives?
Chromadex's management team includes the folowing people:
- Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)
- Mr. Robert N. Fried, CEO & Director (Age 59)
- Mr. Kevin M. Farr, Chief Financial Officer (Age 61)
- Mr. Ben Shichman, Chief Technology Officer
- Dr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation
How do I buy shares of Chromadex?
Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chromadex's stock price today?
One share of CDXC stock can currently be purchased for approximately $3.9950.
How big of a company is Chromadex?
Chromadex has a market capitalization of $220.87 million and generates $31.56 million in revenue each year. The company earns $-33,320,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Chromadex employs 100 workers across the globe.
What is Chromadex's official website?
How can I contact Chromadex?
Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]
MarketBeat Community Rating for Chromadex (NASDAQ CDXC)
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
